For example, data suggest that TP53 mutation status may predict response to standard chemotherapeutic regimens such as fluorouracil or cisplatin,65 which has also recently been demonstrated in OAC.66–68 A prospective randomised trial in oesophageal cancer, aiming at determining this predictive effect of TP53 gene mutations (p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer; http://www.clinicalTrials.gov identifier NCT00525200; http://www.p53.at) has recently completed recruitment. Here, TP53 is linked to esophageal cancer.